An agreement has been struck between Cardium Therapeutics (NYSE: CXM) and researchers at Boston Children's Hospital to assess the medical utility of Cardium's FDA-cleared Excellagen.
Excellagen, Cardium said in a relese, is an aseptically-manufactured bovine collagen homogenate configured into a staggered array of three-dimensional molecules forming a flowable, biocompatible and bioactive structural matrix that can promote cellular adhesion, migration and proliferation to stimulate tissue formation. The collaborative effort will look at its use as a delivery scaffold to seed certain fetal stem cells for ex-vivo engineering of tissue grafts, for transplantation into infants to repair prenatally diagnosed birth defects.
The autologous mesenchymal fetal stem cells are derived prenatally from infants, Cardium said, with a medical defect requiring life-saving tissue repairs. While additional proof of concept studies are currently underway, the company said preliminary pre-clinical research has confirmed that Excellagen collagen homogenate maintains mesenchymal fetal stem cell viability.
"Boston Children's team has made remarkable progress in the field of tissue regeneration and surgical repair of prenatally diagnosed congenital defects," Christopher J. Reinhard, chairman and CEO of Cardium, said. "We believe that Excellagen has an opportunity serve as a delivery platform in the field of stem cell therapy and we look forward to continuing to work with the Boston Children's team to help make their innovative therapeutic vision a new standard of care, and potentially advance stem cell therapies toward commercialization.